Format

Send to

Choose Destination
See comment in PubMed Commons below
Ned Tijdschr Geneeskd. 2006 Jun 10;150(23):1286-90.

[The search for better markers for prostate cancer than prostate-specific antigen].

[Article in Dutch]

Author information

1
Erasmus MC, Josephine Nefkens Instituut, Afd. Urologie, Postbus 1738, 3000 DR Rotterdam. e.schenk-braat@erasmusmc.nl

Abstract

Prostate-specific antigen (PSA) is currently the most important biochemical marker for the diagnosis of prostate cancer. Because of the limited specificity of PSA, clinically irrelevant tumours and benign abnormalities are also detected that potentially lead to over-treatment and the accompanying physical and emotional burden for the patient. In addition, PSA is used as an indicator of progression or clinical response after treatment for prostate cancer, but the prognostic value of this marker is limited. Current studies are evaluating a number of alternative markers, such as PSA-related parameters, human kallikrein 2, osteoprotegerin and the gene DD3(PCA3), that may improve the specificity of current PSA-based diagnostics and the prognostic value of PSA.

PMID:
16821452
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center